SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001387131-23-007603
Filing Date
2023-06-16
Accepted
2023-06-15 18:21:47
Documents
16
Period of Report
2023-05-24
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 8-K admp-8ka_052423.htm   iXBRL 8-K/A 27334
2 CONSENT OF BF BORGERS CPA PC. ex23-1.htm EX-23.1 3042
3 AUDITED FINANCIAL STATEMENTS OF DMK PHARMACEUTICALS ex99-1.htm EX-99.1 145670
4 UNAUDITED FINANCIAL STATEMENTS OF DMK PHARMACEUTICALS ex99-2.htm EX-99.2 81603
5 UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL INFORMATION ex99-3.htm EX-99.3 292117
  Complete submission text file 0001387131-23-007603.txt   785796

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20230525.xsd EX-101.SCH 2998
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20230525_lab.xml EX-101.LAB 34240
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20230525_pre.xml EX-101.PRE 22385
10 EXTRACTED XBRL INSTANCE DOCUMENT admp-8ka_052423_htm.xml XML 3703
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36242 | Film No.: 231018854
SIC: 2834 Pharmaceutical Preparations